A novel precision-based tool in Y90, tumors w/ incomplete response had more ‘underdosed tumor’ (<100 Gy) on post PET/CT. Threshold analysis → ≥28% tumor got <100 Gy, odds of incomplete response ↑ (OR 75, univariate). Congrats @KnightsOfNhi, @AmmarSarwarIRad , & team @BIDMCVIR!
Been MIA, but your girl's been grinding. #Irad highlights from this week: mesenteric embo, CDT for CLTI, kypho/osteocool ablation x2, TIPS revision, LE venogram, hangman #filterout, and a Friday night special: PE thrombectomy 😵💫
We took a comprehensive look at the landscape of combination therapies of HCC, published today in @radiology_rsna@RSNA ! This state-of-the-art review should be a useful read for all disciplines involved in multi-disciplinary HCC care. Full article: https://t.co/67biFHNhGd
In this intensive @SIO_Central program, physicians can expect lectures, case reviews, and hands-on learning to help them implement or expand clinical techniques in their practices. And, our own Dr. Moussa is a co-course director!
Learn more/register: https://t.co/zh1CTXIU46
Good luck to our 6 grads!!! June always hits hard with graduation - this year is no different, what an *amazing* class. You certainly made my job easy for me and brought countless laughs and memories. @BIDMCVIR will always be your home but go get ‘em 👊
📰#SIR24SLC News:
🎉Congratulations to Dr. Weinstein for receiving one of the @JVIRmedia Paper of the Year awards for his hand-motion work!
🎉Congrats also to @AmmarSarwarIRad, who received an award for having one of the most downloaded papers in 2023: https://t.co/qMPX6qhkKe
📢 NEW from @JVIRmedia: Comparing Microwave Ablation (MWA) vs Cryoablation (CA) for small renal masses!
A 12-year single-center study offers valuable insights. Let's break it down! 📊🔬 @SIRspecialists
Study Details:
• 279 small renal masses (≤ 4cm) in 257 patients
• Median age: 71 years
• CA: 191 cases; MWA: 88 cases
• Evaluated: Adverse events, treatment effectiveness, survival rates 🔎
Key Results:
• MWA: 100% technical success
• CA: 1/191 needed retreatment
• No significant impact on renal function post-treatment (CA: p=0.76, MWA: p=0.49)
• No major differences in local recurrence, adverse events, or survival rates 📈🩺
In-Depth Analysis:
• CA used for larger (p<0.01), more complex lesions (p=0.03)
• Propensity score matching showed:
🔹 Similar local recurrence rates (p=0.39)
🔹 Comparable adverse event rates (p=0.20)
🔹 Equivalent cancer-free & overall survival (p=0.76, p=0.19) 🔍
�� Conclusion: Both MWA & CA show high technical success and effective local disease control. Cancer-specific survival rates are similar. CA's higher adverse event rates may be due to treating larger lesions.
Read the full study: https://t.co/QiOyUQI0nM
A big thank you to the authors for their contribution @AmandaSmolockMD, @kantonIR, @DrRobertAdamo, & team! 🙏
How might these findings influence your approach to treating small renal masses? Stay informed on the latest research with our newsletter: https://t.co/s4KXlO0vPJ
@UWiscRadiology @JEFFUrology @JeffCVIR
#VIR #iRads #InnovationInMedicine #MedEd #EvidenceBasedMedicine #Healthcare #ClinicalOutcomes #PatientSafety #MedicalResearch #CancerTreatment #Urology #RenalCellCarcinoma #Oncology #Radiology #InterventionalRadiology